• Home
  • Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.

Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.

Author List
Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, Stock PG
Publication
Transplantation
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1418994
Publication Year
2000
PubMed ID
10670644
Publication Title
Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, Stock PG. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation. 2000 Jan 27; 69(2):307-11.